Abstract | BACKGROUND: AIMS: METHODS: Prospective, multicentric, balanced, randomized, double blind, parallel group comparison clinical trial. Each patient received 40 mg pantoprazole plus placebo or 300 mg ranitidine plus placebo once daily for 2 weeks; if patients had not healed endoscopically by then, treatment was continued for two more weeks, with a final endoscopy. RESULTS: 163 protocol-correct patients were analyzed: 82 for pantoprazole group and 81 for ranitidine group. Healing rates at week 2 were 72% for pantoprazole and 51% for ranitidine (p < 0.01) and correspondingly 95 and 86% at week 4. The percentage of patients suffering from pain declined faster in the pantoprazole group. Both products were well tolerated and safe. CONCLUSIONS:
|
Authors | M Dibildox, K Rose, J Tomás-Pons, R Fischer, S Gallo |
Journal | Revista de gastroenterologia de Mexico
(Rev Gastroenterol Mex)
1996 Jul-Sep
Vol. 61
Issue 3
Pg. 193-8
ISSN: 0375-0906 [Print] Mexico |
Vernacular Title | Superioridad del pantoprazol sobre la ranitidina en el tratamiento de la úlcera duodenal. Experiencia clínica Mexicana. Grupo Mexicano de Estudio del Pantoprazol en Ulcera Duodenal. |
PMID | 9102740
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
- Benzimidazoles
- Sulfoxides
- Ranitidine
- Pantoprazole
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Adolescent
- Adult
- Aged
- Anti-Ulcer Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Double-Blind Method
- Duodenal Ulcer
(drug therapy)
- Humans
- Mexico
- Middle Aged
- Omeprazole
(analogs & derivatives)
- Pantoprazole
- Prospective Studies
- Ranitidine
(therapeutic use)
- Sulfoxides
(therapeutic use)
|